By the numbers: As the pandemic biotech boom fades, it's beginning to look a lot like 2019 — or before
This year, with Nasdaq iced over, everything is falling behind. A quick turn to CDER’s approvals for the year reveals that the group has stamped …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
